ProCE Banner Activity

Understanding GLP-1 RAs: Why They Are an Effective Option in Managing Patients With Type 2 Diabetes

Clinical Thought

There’s a wealth of new data on the benefits of glucagon-like peptide-1 receptor agonists (GLP-1s). Read an expert’s review on how these agents work to provide glycemic, cardiovascular, and renal benefits in patients with type 2 diabetes (T2D).

Released: February 15, 2022

Expiration: February 14, 2023

No longer available for credit.



Richard E. Pratley

Richard E. Pratley, MD

Samuel E. Crockett Chair in Diabetes Research
Medical Director
AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins University School of Medicine
Orlando, Florida


This activity is supported by an educational grant from Novo Nordisk.

Provided by

ProCE Banner

Target Audience

NPs and PAs who practice in endocrinology, cardiology, and primary care


Dr Pratley: consulting fees/fees for non CME/CE services: Bayer AG, Corcept Therapeutics Incorporated, Dexcom, Gasherbrum Bio, Inc, Hengrui (USA) Ltd., Merck, Pfizer, Rivus Pharmaceuticals Inc., Sanofi, Scohia Pharma Inc., Sun Pharmaceuticals; contracted research/consulting fees/fees for non CME/CE services: Hanmi; Novo Nordisk; contracted research: Metavention, Poxel SA.

None of the members of the PCE staff have any relevant relationships to disclose.


Clinical Thought


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Additional Information

Program Medium

This program has been made available online.